Bellinda L King-Kallimanis

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Topics

Patient Reported Outcomes

Placebo Controlled

Top Venues

Clinical trials (London, England)

Journal of the National Cancer Institute

JCO clinical cancer informatics

This page only lists publications with an associated author ORCID identifier.

Publications

Bellinda L King-Kallimanis, Vishal Bhatnagar, Erica G Horodniceanu, Ting-Yu Chen, Paul G Kluetz
Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events. Clinical trials (London, England) 19 (3) (2022)
Bellinda L King-Kallimanis, Jill Feldman, Manraj N Kaur
Real-World Symptom Monitoring With Patient-Reported Outcome Measures: What Can We Use This Data for? JCO clinical cancer informatics 6 (2022)
Paul G Kluetz, Bellinda L King-Kallimanis, Daniel Suzman, Elaine Chang, Michael M Brave, Chana Weinstock, Vishal Bhatnagar, Julia A Beaver, Meredith K Chuk
Advancing Assessment, Analysis, and Reporting of Safety and Tolerability in Cancer Trials. Journal of the National Cancer Institute 113 (5) (2022)
Jessica K Roydhouse, Bellinda L King-Kallimanis, Pourab Roy, Chana Weinstock, Danielle Krol, Selena R Daniels, Daniel L Suzman, Julia A Beaver, Paul G Kluetz
Exploration of baseline patient-reported side effect bother from cancer therapy. Clinical trials (London, England) 17 (3) (2020)
Bellinda L King-Kallimanis, Lynn J Howie, Jessica K Roydhouse, Harpreet Singh, Marc R Theoret, Gideon M Blumenthal, Paul G Kluetz
Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions. Clinical trials (London, England) 16 (3) (2019)